Myrobalan Therapeutics
Medford
About Myrobalan Therapeutics
Myro Therapeutics is a biotechnology company that focuses on the development of therapeutic solutions for Central Nervous System (CNS) disorders. The company aims to address unmet medical needs related to neurodegenerative, demyelinating, and neuropsychiatric disorders through innovative therapeutics. Myrobalan leverages extensive expertise in drug discovery and the neurological mechanisms involved in demyelination and neuroinflammation to develop therapeutic candidates that are highly selective and capable of penetrating the brain, specifically aimed at addressing CNS disorders with considerable unmet medical needs. Myrobalan is dedicated to a transformed future where individuals suffering from degenerative CNS disorders have access to safe and effective medications that provide restorative potential.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $34.2M
- Funding stage: Early Stage Venture
- Last round: Grant (Mar 2025)
- Website: myrotx.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/myrobalan-therapeutics-48344 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.